The germline HLA-I evolutionary divergence was strongly associated with the survival benefit of metastatic melanoma or NSCLC patients treated with anti-CTLA-4 or anti-PD-1/-PD-L1 (51). Here, CTLA4 is linked to non-small cell lung carcinoma.